Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in Ghana, West Africa. This is the sixth country to take part in RECOVERY, joining Indonesia, Nepal, South Africa, Vietnam, and the United Kingdom.

Aerial image of town in Ghana

Since March 2020, the RECOVERY Trial has discovered three effective treatments for COVID-19: the inexpensive steroid dexamethasonethe arthritis drug tocilizumab; and a monoclonal antibody treatment, now known as Ronapreve. However, as the pandemic continues to affect both high and lower income countries, and with the constant threat of new coronavirus variants, treatments are needed that are suitable for a wide range of patients and healthcare systems. Consequently, RECOVERY International was launched in February 2021.

Professor Sir Peter Horby, Joint Chief Investigator of RECOVERY, said: ‘I am thrilled to welcome Ghana to the RECOVERY endeavour to improve the care of patients with severe COVID-19. COVID-19 affects everyone, and we need treatments for everyone, wherever they are and whatever level of healthcare is available to them.’ 

In Ghana, RECOVERY will initially focus on whether using a higher dose of the anti-inflammatory treatment dexamethasone has an even greater effect than the standard doses of the drug previously shown to save lives by the RECOVERY trial. It is likely that empagliflozin, a routine treatment for type 2 diabetes, will also be added to the study in Ghana soon.

The first Ghanaian hospitals taking part in RECOVERY are the Ghana Infectious Disease Centre, Accra, and the Komfo Anokye Teaching Hospital, Kumasi. The study will be open to all hospital patients admitted with confirmed COVID-19. All participants will receive the usual care; some will additionally receive one of the treatments being investigated.

The expansion of RECOVERY International to Ghana is a partnership between the University of Oxford and the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR).

The full story is available on the RECOVERY website

Similar stories

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

The GRAM Project has moved

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.

The RECOVERY Trial - two years on

One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.